Kornimate/medical-research-clean huggingface dataset:
bone marrow grafting for leukemia and lymphoma

Conditions: Leukemia; Lymphoma; Hematologic Diseases

Summary: the purpose of this study is to obtain tissue samples for ongoing studies regarding transplant outcomes and complications.

the purpose of this study is to acquire critical tissue and biological samples that can be evaluated to elucidate underlying mechanisms of disease control, transplant related complications and overall outcomes

Eligibility criteria:
inclusion criteria:- all hematopoietic cell transplant recipients and donors who agree to participate exclusion criteria:- subject does not agree to participate
ivtcc 2.0: a prospective multicenter ventricular tachycardia catheter ablation registry

Conditions: Ventricular Arrhythmia; Ventricular Tachycardia; Premature Ventricular Contraction (PVC); Cardiomyopathy

Summary: this is a prospective multi-center international registry. the objective of this registry is to collect prospective data on patients undergoing catheter ablation for ventricular tachycardia (vt) and premature ventricular contractions (pvc). the registry will be used for clinical monitoring, research, and quality improvement purposes.

sudden cardiac death (scd), predominantly due to ventricular tachyarrhythmias, is a leading cause of mortality in the united states and around the world. catheter ablation of ventricular arrhythmias has proven efficacious in reducing the burden of arrhythmias and reducing implantable cardiac defibrillator (icd) shocks. the aim of this study is to create a prospective international database registry that will allow for better assessment of the outcomes of catheter ablation of ventricular arrhythmias. the registry, with approximately 30 participating centers, will help to identify the overall success rates and associated benefits of the procedure and provide more comprehensive data on understudied populations and treatment.

Eligibility criteria:
inclusion criteria: - all patients undergoing catheter ablation for ventricular tachycardia (vt) or premature ventricular contractions (pvcs).

Keywords: arrhythmia cardiac conduction system disease sudden cardiac death implantable cardiac defibrillator (icd)
exercise training after an acute blood clot

Conditions: VTE

Summary: patients after an acute blood clot in the veins are at risk for leg-related complications such as pain, swelling, and immobility. in addition, the occurrence of blood clots can have major implications for personal health including weight gain, blood clot recurrence and impairment in cardiovascular functioning. the goal of this study is to determine whether aerobic exercise training is a therapeutic strategy to offset risk factors for recurrent blood clots or leg complications.

cardiac rehabilitation (cr), a formalized exercise and behavioral modification program, is the cornerstone of secondary prevention for heart disease. implementation of cr early after an acute myocardial infarction (mi) is associated with improved cardiac function and survival. as such, cr is now standard of care for a majority of hospital-based discharge programs following coronary events. in stark contrast, no similar program exists following an acute venous thromboembolism (vte or blood clot), despite a high rate of limb and respiratory disability after vte, shared risk factors with heart disease, and known beneficial impact of exercise training on vte complications (e.g. post-thrombotic syndrome, pts). body weight is a key modifiable risk factor driving risk of incident and recurrent vte. obese patients with prior vte have a 2-fold higher risk of a second vte compared to normal weight patients.(1) importantly, vte recurrence risk escalates if weight control is not established. weight gain after acute dvt is common, with a mean 7% increase over 6 months.(2) to date, however, there is limited evidence regarding whether early initiation of exercise training following acute dvt is safe and feasible and mitigates weight gain associated with a vte diagnosis. previously, a significant decrease in body weight and fat mass loss was demonstrated utilizing high-caloric expenditure exercise in the cr setting.(3) delineating the impact of high-caloric expenditure exercise to induce weight loss and reduce vte complications and recurrence is a critical first step toward evaluating the role of early post-vte rehabilitation in the clinical setting.

Eligibility criteria:
inclusion criteria: * diagnosis of acute unprovoked proximal or distal dvt \>= 6 weeks * on anticoagulation therapy * patient self-report of ability to walk 10 minutes without interruption or pain * age \>=16 and \<80 * willingness to participate in exercise rehabilitation program at tilley drive south burlington exclusion criteria: * symptomatic pe, defined as 1) right heart strain as assessed by computed tomography or echocardiogram, 2) resting hypoxia - resting oxygen saturation \<92% * provoked vte: major surgery, trauma, or pregnancy * medical condition that alters ability to walk for exercise

Keywords: vte exercise diet weight loss dvt pe
red yeast rice and subclinical atherosclerosis in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: to evaluate the effect of red yeast rice on subclinical atherosclerosis in patients with rheumatoid arthritis


Eligibility criteria:
inclusion criteria: * patients with a definite diagnose of rheumatoid arthritis(ra) were included if they met the classification criteria for ra established by the american rheumatism association (acr) and european league against rheumatism (eular) in 2010 * aged from 18 to 75 years * without conflict to the written, informed consent signed prior to the enrollment * no severe hepatic or renal disorders * no known carotid artery stenosis * no coagulation disorders * no hypertension exclusion criteria: * being in pregnancy, lactation period or under a pregnancy plan * being allergic to the test drug * not compatible for the trial medication * without full legal capacity
pet imaging in patients with suspected cardiac sarcoidosis

Conditions: Cardiac Sarcoidosis

Summary: gallium-68 dotatate is a radioactive tracer, a type of imaging drug that is labeled with a radioactive tag and injected into the body, which is approved by the u.s. food and drug administration (fda) to diagnose certain tumors. the study will see how the tracer is taken up in your heart before and after treatment using an imaging scan called positron emission tomography / computed tomography (pet/ct). investigators are doing this research study to find out if dotatate can help doctors diagnose people with cardiac (heart) sarcoidosis better as well as serve as a follow-up monitoring tool for a response to therapy.


Eligibility criteria:
inclusion criteria: 1. participants will be ≥ 18 years of age 2. history of biopsy-proven sarcoidosis or suspected sarcoidosis based on standard clinical imaging (e.g. fdg pet/ct, mri) without biopsy confirmation 3. clinical suspicion of cardiac involvement defined as the presence of any of the following: 1. high degree a-v nodal block 2. complete bundle branch block 3. reduced left or right ventricular systolic fusion 4. any cardiac arrhythmia 5. chest pain, dyspnea or syncope without clear etiology 4. fdg pet/ct scan demonstrating abnormal myocardial fdg uptake 5. participants must be informed of the investigational nature of this study and be willing to provide written informed consent and participate in this study in accordance with institutional and federal guidelines prior to study-specific procedures exclusion criteria: 1. females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential at screening. 2. history of neuroendocrine tumors 3. currently taking the medication octreotide 4. currently on total parenteral nutrition (tpn) 5. inability to tolerate imaging procedures in the opinion of an investigator or treating physician 6. any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study
quality of life evaluation (sf-36) in patients with permanent hypoparathyroidism after total thyroidectomy (qol-hypopara)

Conditions: Hypoparathyroidism; Quality of Life

Summary: persistent hypoparathyroidism is an underestimate but major complication of total thyroidectomy. the hypothesis of the investigators is that the mental health is impaired in hypoparathyroid patients compared with thyroidectomized patients without hypoparathyroidism. the investigators evaluated the quality of life using the sf-36 survey in comparison with a control population of patients thyroidectomized but free from this complication. the voice quality, the cardiovascular risk, the kidney function and the incidence of urinary lithiasis were also evaluated.

persistent hypoparathyroidism is an underestimate but major complication of total thyroidectomy. in this retrospective, observational, multicentre study, the investigators evaluated the quality of life using the sf-36 survey in comparison with a control population of patients thyroidectomized but free from this complication. patients in six centers in france (angers, le mans, limoges, nancy, nantes, la pitié-salpétrière) and in the association "hypoparathyroïdisme france" were contacted by mail. the primary endpoint was the mental health. the physic and global quality of life scores were assessed as secondary endpoints. medical and vhi surveys were also send to the patients. the voice quality, the cardiovascular risk, the kidney function and the incidence of urinary lithiasis were also evaluated.

Eligibility criteria:
inclusion criteria: * patients operated of total thyroidectomy * patients suffering from persistent hypoparathyroidism defined as serum pth inferior to 15 pg/ml 6 months after the surgery, requiring vitamin-calcic supplementation. * age superior to 18 * answering the survey exclusion criteria: * pregnancy at the time of the study * age inferior to 18 or adult under guardianship * patients with vitamino-calcic supplementation without serum pth measurement * cause of hypoparathyroidism other than post-operatory.
effects of macular buckle versus vitrectomy on macular hole and macular detachment in highly myopic eyes

Conditions: Macular Holes; High Myopia; Macular Detachment

Summary: full-thickness macular hole associated with macular detachment is a one of the maculopathies of high myopia. there is controversy in the primary treatment for this situation. this study will compare the effects of macular buckling versus vitrectomy in a cohort of highly myopic eyes with this situation.

a randomized, open label, single center study comparing the efficacy of macular muckle + gas injection versus internal limiting membrane peeling + gas tamponade on full-thickness macular hole associated with macular detachment in eyes with high myopia.

Eligibility criteria:
inclusion criteria: * axial length ≥ 26.5 mm or refractive error (spherical equivalent) ≥ 8.0 diopter * full-thickness macular hole * macular retinal detachment * evidence of posterior staphyloma on clinical examination exclusion criteria: * macular detachment which extended to the peripheral retina (i.e., extension beyond the major vascular arcades in more than one quadrant) * a history of vitrectomy or scleral buckling * intraocular active hemorrhage or inflammation * any media opacity which precluded imaging or clinical evaluation of the macula

Keywords: macular buckling full-thickness macular hole macular detachment internal limiting membrane peeling high myopia
safety and efficacy of autologous cultured adipocytes in patient with depressed scar

Conditions: Depressed Scar

Summary: autologous cultured adipocytes (antg-adip) is produced by well-established techniques including cell harvesting from lipoaspirates, expansion of adipose tissue derived stem cells, and differentiation into pure and immature adipocytes. this was an open-label, dose-escalation study. patients are given subcutaneous injection of antg-adip and followed for 12 weeks according to the clinical trial protocol.


Eligibility criteria:
inclusion criteria: * older than 19 years * depressed scar less than volume of 5 ml * negative for urine beta-hcg for women of childbearing age * agreement to participate, with signed informed-consent exclusion criteria: * failure to meet inclusion criteria * any immune-suppressive drug, corticosteroid or cytotoxic drug within the previous 30 days * allergy to bovine-derived materials * diagnosis of cancer, aids, hbv or hcv. * patient has a lot of hairs or a tattoo on depressed site * insufficient adipose tissue for manufacturing of antg-adip * patient has depressed scar caused by a malignant tumor * patient whom investigator consider is not suitable in this study
zika and neurodevelopment among infants in grenada

Conditions: Zika Virus Infection; Neurocognitive Deficit; Development, Child; Neurodevelopmental Abnormality

Summary: implement a randomized controlled trial, evidence-based, culturally adapted, environmental enrichment intervention for the purpose of enhancing neurocognitive outcomes among zika exposed children.

the intervention group received up to twelve 1-hour weekly visits by trained and experienced grenadian parent and infant relationship specialists who provided home-based interventions as part of the saving brains grenada project. the environmental enrichment intervention is a brain-based program that teaches parents about brain development in young infants and skills for building a strong social-emotional connection that stimulates brain development and maximizes neurocognitive function. a detailed intervention manual was developed and used as a guide for the intervention specialists. neurocognitive outcomes in the intervention and control group were assessed pre and post intervention by a separate and blinded assessment team.

Eligibility criteria:
inclusion criteria: * must be actively enrolled in the pre-existing zika cohort study * infant must be alive and living with a parent/guardian at the time of recruitment * infant must be between 24-27 months at the time of recruitment exclusion criteria: * any infants older than 27 months * persons not enrolled in the pre-existing zika cohort study
overcoming therapeutic inertia among adults recently diagnosed with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: therapeutic inertia may result from providers, patients, and/or systems, but can be detrimental to a patients' health by putting them at risk for diabetes complications, though addressing it early can mitigate some of its effects. in type 2 diabetes (t2d) care, this may look like failure to initiate metformin therapy early in the disease course. this project aims to evaluate the effects of proactive outreach by a non-physician clinician (accountable population manager \[apm\]) to patients with newly diagnosed type 2 diabetes. the team hypothesizes individuals receiving proactive outreach by an apm will be more likely to achieve glycemic targets at 6 months following start of the intervention.

this is a 3-arm randomized clinical trial comparing patients in the following arms: 1) usual type 2 diabetes care, 2) primary care physicians have been exposed to physician education on therapeutic inertia, and 3) primary care physicians have been exposed to physician education on therapeutic inertia and patients are referred to apm proactive outreach. the apm is a non-physician clinician, including clinical pharmacists and nurses. eligible members will be identified via electronic health record (ehr) data in two stages: 1) identification of individuals with newly diagnosed t2d, 2) identification of the subset of newly diagnosed individuals with metformin-related therapeutic inertia. the content of the apm visit will be the same as what currently occurs in standard diabetes care, including discussing the risks and benefits of pharmacologic treatment and initiating treatment (with patient agreement), supporting medication adherence, and providing education and support for overall t2d management. the main outcome will be hba1c at 6, 12, and 18 months post-intervention.

Eligibility criteria:
inclusion criteria: * kaiser permanente northern california (kpnc) member age 18-74 * incident type 2 diabetes * patient of primary care physician (pcp) working in the randomized service areas * identified metformin-related therapeutic inertia * at least one a1c 6.5-7.9 from 4 months post-diagnosis up to the time of randomization exclusion criteria: * evidence of preceding t2d diagnosis * pregnant at the time of t2d diagnosis * likely to have type 1 diabetes
quizartinib or placebo plus chemotherapy in newly diagnosed patients with flt3-itd negative aml

Conditions: Leukemia

Summary: this study will compare the effects of quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed fms-like tyrosine kinase 3 (flt3)-internal tandem duplication (itd) negative acute myeloid leukemia (aml).

this is a clinical trial to compare the effect of quizartinib versus placebo (administered with standard induction and consolidation chemotherapy, then administered as maintenance therapy for up to 36 cycles) on the primary endpoint of overall survival (os) in adult patients with newly diagnosed fms-like tyrosine kinase 3 (flt3)-internal tandem duplication (itd) negative acute myeloid leukemia (aml). participants will be tested for flt3-itd mutation status in a central laboratory using a validated assay.

Eligibility criteria:
key inclusion criteria: * must be competent and able to comprehend, sign, and date an ethics committee (ec)- or institutional review board (irb)-approved informed consent form (icf) before performance of any trial-specific procedures or tests. * ≥18 years or the minimum legal adult age (whichever is greater) and 70 years (at screening). * newly diagnosed, morphologically documented primary aml based on the world health organization (who) 2016 classification (at screening) * eastern cooperative oncology group (ecog) performance status (at the time the participant signs their icf) of 0-2. * participant is receiving standard "7+3" induction chemotherapy regimen as specified in the protocol key exclusion criteria: * diagnosis of acute promyelocytic leukemia (apl), french-american-british classification m3 or who classification of apl with translocation, t(15;17)(q22;q12), or bcr-abl positive leukemia (ie, chronic myelogenous leukemia in blast crisis); participants who undergo diagnostic workup for apl and treatment with all-trans retinoic acid (atra), but who are found not to have apl, are eligible (treatment with atra must be discontinued before starting induction chemotherapy). * diagnosis of aml secondary to prior chemotherapy or radiotherapy for other neoplasms or autoimmune/rheumatologic conditions. * diagnosis of aml secondary to myelodysplastic syndrome (mds) or a myeloproliferative neoplasm (mpn) or mds/mpns including cmml, acml, jmml and others. * participants with newly diagnosed aml with flt3-itd mutations (flt3-itd \[+\]) present at ≥5% vaf (or ≥0.05 sr) based on a validated flt3 mutation assay. * prior treatment for aml, except for the following allowances: 1. leukapheresis; 2. treatment for hyperleukocytosis with hydroxyurea; 3. cranial radiotherapy for central nervous system (cns) leukostasis; 4. prophylactic intrathecal chemotherapy; 5. growth factor/cytokine support.

Keywords: acute myeloid leukemia quizartinib flt3 flt3-itd chemotherapy flt3-wt
effects of ocular electroacupuncture on oculomotor nerve palsy

Conditions: Oculomotor Nerve Palsy

Summary: the purpose of the study is to testify the efficacy of treating oculomotor nerve palsy with ocular electroacupuncture or ocular acupuncture, and to compare the efficacy between these two interventions.

the purpose of the study is to testify whether ocular electroacupuncture or ocular acupuncture is effective for oculomotor nerve palsy (onp), through treating onp patient for 6 weeks, using self-invented acupoints according to anatomy of extraocular muscles innervated by oculomotor nerve, and using sham acupuncture as controlled group, and try to provide clinical evidence for promoting these new techniques.

Eligibility criteria:
inclusion criteria; 1. patient with confirmed diagnosis of complete oculomotor nerve palsy (with or without mydriasis) made by neurologist or ophthalmologist; 2. patient in stable condition after treatment for primary disease; 3. age between 18 to 80 years old without gender limitation; 4. haven't received acupuncture intervention for onp before; 5. patient with conscious, willing to cooperate and voluntarily agreed to participate and signed informed consent forms. exclusion criteria: 1. those with other diagnosed medical conditions known to contribute to onp symptoms, such as thyroid disease, myasthenia gravis, mitochondrial myopathy, congenital strabismus or received strabismus surgery; 2. those with color blindness, dyschromatopsia or abnormal retinal correspondence couldn't complete computerized diplopia test; 3. those with serious medical conditions that might limit their participation; 4. those with eye or other location with serious infections; 5. women who had a positive pregnancy test or who were planning to become pregnant during the study period; 6. those with bleeding tendency, blood coagulation dysfunction or taken anticoagulant drugs; 7. who had participate in other clinical trials, which may affect the results.

Keywords: electroacupuncture oculomotor nerve palsy rehabilitation diplopia ocular motility disorder
to assess the efficacy and safety of pt010 compared to pt009 in subjects with moderate to very severe chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this is a 12-week chronic-dosing study to assess the efficacy and safety of bgf mdi compared to bff mdi in subjects with moderate to very severe copd.

this is a multicenter, randomized, double-blind, parallel-group, 12-week chronic-dosing study to assess the efficacy and safety of bgf mdi compared to bff mdi in subjects with moderate to very severe copd. the study has a total of 7 visits over a screening period of up to 28 days and a treatment period of 12 weeks followed by a telephone follow-up call 14 days after the last dose of study drug.

Eligibility criteria:
key inclusion criteria: * signed informed consent * subjects with an established clinical history of copd * forced expiratory volume in 1 second (fev1)/forced vital capacity (fvc) ratio must be \<0.70 and fev1 must be \<80% predicted normal value * all subjects must have been on 2 or more inhaled maintenance therapies for the management of their copd for at least 6 weeks prior to screening * current or former smokers with a history of at least 10 pack-years of cigarette smoking * women of non-childbearing potential * women of childbearing potential and sexually active agree to prevent pregnancy by using acceptable contraceptive methods consistently key exclusion criteria: * significant diseases or conditions other than copd, which in the opinion of the investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study * women who are pregnant or lactating, or are planning to become pregnant during the course of the study, or women of childbearing potential who are not using an acceptable method of contraception * current diagnosis of asthma * uncontrolled sleep apnea * other serious respiratory disorders * hospitalized due to poorly controlled copd within 6 weeks * poorly controlled copd * immune deficiency and/or severe neurological disorders affecting control of the upper airway * hypersensitivity to β2-agonists, corticosteroids, or muscarinic anticholinergics